Announcements Trials
Browse Landscape

Phase

Phase 1 5Phase 1/2 4Phase 3 3Phase 2 2

Status

Terminated 1Recruiting 1Completed 1

Sponsor Class

INDUSTRY 3

Study Type

Interventional 3

Sponsor

Cancer Type

Plasma cell 2Myeloid 1Lymphoid 1Classical hematology 1

Conditions

Breast Neoplasms 1129Carcinoma, Non-Small-Cell Lung 718Neoplasms 546Prostatic Neoplasms 505Colorectal Neoplasms 439Multiple Myeloma 338Lung Neoplasms 310Neoplasm Metastasis 289Leukemia, Myeloid, Acute 263Stomach Neoplasms 248Carcinoma, Hepatocellular 246Ovarian Neoplasms 225Rectal Neoplasms 211Colonic Neoplasms 204Lymphoma, Follicular 200Lymphoma 199Leukemia 190Uterine Cervical Neoplasms 181Head and Neck Neoplasms 174Pancreatic Neoplasms 172Lymphoma, Non-Hodgkin 167Leukemia, Lymphocytic, Chronic, B-Cell 166Lymphoma, Large B-Cell, Diffuse 163Recurrence 162Melanoma 158Precursor Cell Lymphoblastic Leukemia-Lymphoma 154Squamous Cell Carcinoma of Head and Neck 147Pain 141Urinary Bladder Neoplasms 139Brain Neoplasms 133

Interventions

Vorinostat 1Bortezomib 111-(2-pyrrolidin-1-ylethoxy)-14,19-dioxa-5,7,26-triazatetracyclo(19.3.1.1(2,6).1(8,12))heptacosa-1(25),2(26),3,5,8,10,12(27),16,21,23-decaene 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Phase 3 × Interventional × Hemorrhagic Disorders × Clear all
NCT06963216 2026-05-11

A Study Investigating Coagadex in the Treatment AFXD Associated With AL Amyloidosis

Kedrion S.p.A.

Phase 3 Recruiting
15 enrolled
Plasma cell

Immunoglobulin Light-chain Amyloidosis, Blood Coagulation Disorders, Factor X Deficiency, Hematologic Diseases, Hemorrhagic Disorders

NCT02055781 2021-11-18

PAC326

CTI BioPharma

Phase 3 Terminated
311 enrolled 12 charts
Classical hematologyMyeloid

Anemia, Bone Marrow Diseases, Hematologic Diseases, Hemorrhagic Disorders, Myeloproliferative Disorders, Polycythemia Vera, Splenomegaly, Thrombocythemia, Essential, Thrombocytopenia, Primary Myelofibrosis

NCT00773747 2021-04-30

Study of Vorinostat (MK-0683) or Placebo, in Combination With Bortezomib in Participants With Multiple Myeloma (MK-0683-088 AMN)

Merck Sharp & Dohme LLC

Phase 3 Completed
637 enrolled 15 charts
LymphoidPlasma cell

Blood Protein Disorders, Cardiovascular Diseases, Hematologic Diseases, Hemorrhagic Disorders, Immune System Diseases, Immunoproliferative Disorders, Lymphoproliferative Disorders, Multiple Myeloma, Neoplasms, Neoplasms by Histologic Type, Paraproteinemias, Vascular Diseases, Hemostatic Disorders, Neoplasms, Plasma Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡